Drug intelligence / Profile preview

GA-AT0719

Development stage
Unknown
Lead developer
Devintec
Modality
Small Molecules, Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

GA-AT0719 is an oral medical device (Class IIa) developed by Devintec Sagl for the management of functional gastrointestinal disorders, specifically functional abdominal bloating and distension. It is a combination product consisting of simethicone and Acti-Abdo, a proprietary standardized complex of herbal extracts derived from Althaea officinalis (marshmallow) and Zingiber officinale (ginger). Simethicone acts as a surfactant to reduce the surface tension of gas bubbles in the gastrointestinal tract, facilitating their coalescence and removal. The herbal components provide complementary effects: ginger acts as a prokinetic and antispasmodic agent to improve gastric motility, while marshmallow root provides demulcent properties to soothe the intestinal mucosa. GA-AT0719 has been evaluated in clinical trials, demonstrating superior efficacy compared to simethicone alone in reducing symptoms of excessive intestinal gas and bloating, including in patients with small intestinal bacterial overgrowth (SIBO).

Brand names
Abdo-Gas
02

Targets

mAChR (Muscarinic acetylcholine receptors)HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on GA-AT0719.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GA-AT0719.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call